A 25-year-old healthy white woman had a known 2-year history of progressive intermittent headaches, hot flushes, diaphoresis and hypertension noted to be 145/90 mm Hg before medical therapy was initiated. Despite the progressive introduction of an ACE inhibitor (ramipril), calcium channel blocker (amlodipine) and an α2-adrenergic agonist (clonidine), her blood pressure unexpectedly continued to rise. She presented to the emergency department at the 2-month mark with a severe headache and a confirmed blood pressure of 165/125 mm Hg. She was fully compliant with the antihypertensive medications in the weeks preceding. She denied current or past symptoms of episodic or sustained tachycardia, palpations, dyspnoea, abdominal pain, fatigue or weight loss. Her only other medication was an oral contraceptive, which had been taken long term. She is a non-smoker and non-drinker with no comorbidities, no recreational drug use or any family history of endocrinopathies.Go to:InvestigationsSustained hypertension was confirmed in both arms and investigations into secondary causes of hypertension were initiated on her hospital admission. A same-day dedicated renal Doppler ultrasound ruled out renal artery stenosis, but incidentally located a unilateral left adrenal mass of 6.5 cm, supporting the possibility of secondary hypertension from adrenal hormone excess. Investigations into the adrenal incidentaloma ruled out excess cortisol or aldosterone as aetiologies of the hypertension when specifically screened. Other tests for secondary hypertension were similarly normal including calcium, parathyroid hormone (PTH) and thyroid (thyroid stimulating hormone [TSH]) measurements. After a several-day delay for test results, the 24-hour urine collection for catecholamines and metanephrines were ultimately reported to have marked elevations of normetanephrine at 38.76 μmol/24 hours (upper limit of normal (ULN) 3.90 μmol/24 hours), catecholamines at 13 700 μmol/24 hours (ULN 630 μmol/24 hours) and norepinephrine 13 652 μmol/24 hours (ULN 505 μmol/24 hours), without an elevation in urinary epinephrine/epinephrine or metanephrines.Given the biochemical evidence for a phaeochromocytoma, an abdominal MRI with gadolinium contrast was performed to confirm the location and was intended to better visualise the adrenal glands. This study (figure 1) confirmed the presence of the left adrenal mass (3.9×4.8×6.5 cm) previously found by ultrasound and unexpectedly also detected a smaller (0.9×1.2×1.2 cm) contralateral adrenal mass on the right. A retrospective review of the original renal Doppler ultrasound did not detect the small right-sided adrenal lesion, perhaps being below the level of detection. The same MRI incidentally found multiple lesions in the pancreas that were suspicious for neuroendocrine tumours and pancreatic cysts. Specific testing for chromogranin A, which is a non-specific marker of neuroendocrine tumours, reported a marked elevation at 334 ng/mL (ULN 110) consistent with the presence of pancreatic neuroendocrine tumours (pNETs). The largest pancreatic mass was medial to the uncinate process (3.7×3.0×5.6 cm) and was solid with areas of necrosis. The other pancreatic masses were significantly smaller, cystic, well defined and uniform in character and were in the body and tail of the pancreas.Open in a separate windowFigure 1Abdominal MRI post-gadolinium administration, highlighting the 6.5×4.8×3.9 cm left adrenal mass with variable intensity/density and a central area of necrosis. The 0.9×1.2×1.2 cm right adrenal mass is not well defined in this image, but several enhancing masses are clustered in the pancreas.While in hospital, focused studies were carried out to determine the functionality of the multiple lesions. An 111In octreotide plus SPECT/CT scan confirmed octreotide avidity only in the uncinate process of the pancreas consistent with a pNET and correlating with the largest pancreatic lesion (figure 2). To confirm the activity of the adrenal masses suspected of being phaeochromocytomas, a 123I-labelled meta-iodobenzylguanidine (MIBG) whole-body scan was performed (figure 3). As shown, there was activity found within both adrenal glands, confirming bilateral functional phaeochromocytomas. The activity was limited to the adrenal glands with no other body sites of increased uptake reported, making paragangliomas or distant metastasis unlikely.Open in a separate windowFigure 2Abnormal octreotide accumulation within the uncinate process of the pancreas correlating with the known mass in this area. Anterior (left) and posterior (right) near whole-body imaging 24 hours after an intravenous dose of 111In-labelled octreotide. SPECT/CT scan not shown but indicated the persistent abnormal octreotide activity within the uncinate process of the pancreas. There is also physiological activity within a loop of large bowel. The adrenal masses seen on MRI do not abnormally accumulate octreotide.Open in a separate windowFigure 3123I-labelled meta-iodobenzylguanidine (MIBG) scan at 24 hours (right side). There is an intense MIBG-avid lesion involving the left adrenal gland corresponding to the large adrenal mass in this location identified on the correlative MR study (left side). Moderately intense uptake is also identified involved in a second lesion involving the right adrenal gland, which is significantly smaller and less intense than the left. No other abnormal foci of increased MIBG uptake are identified.Go to:Differential diagnosisThe rapid development of resistant hypertension in our young patient led us to look for secondary causes of hypertension, which rapidly ruled out renal artery stenosis, hyperthyroidism or calcium elevations as underlying causes. The unexpected finding of a large adrenal mass by renal Doppler ultrasound elevated the possibility of adrenal sources of aldosterone, cortisol or catecholamine excess as possible aetiologies. Screening tests were negative for aldosterone excess (a normal aldosterone:renin ratio was reported) or cortisol excess (normal low-dose dexamethasone suppression test). Strikingly, the urinary norepinephrine and normetanephrines were each elevated at least 10× normal, which gave compelling evidence of a phaeochromocytoma as the underlying cause of the resistant hypertension. The significance of normal levels of epinephrine and metanephrines in this case is discussed below. Both MRI or CT are acceptable imaging modalities to localise phaeochromocytomas prior to surgical excision, with an MRI being more sensitive than CT.1 In our case, the abdominal MRI with contrast detected asymmetrical bilateral adrenal lesions and multiple pancreatic lesions. These findings are consistent with a previous seminal study finding that almost one-fourth of sporadic phaeochromocytomas and more than four-fifths of patients with multifocal tumours have an underlying genetic aetiology that requires genetic analysis.2Genetic testing targets those genes most likely associated with phaeochromocytomas (European–American Pheochromocytoma Registry defined frequency): MEN2 affecting the RET oncogene (23.1%), von Hippel-Lindau (VHL) syndrome affecting the VHL gene (34.7%), neurofibromatosis type 1 (NF-1) affecting the NF1 gene (12.4%) and hereditary paraganglioma–phaeochromocytoma affecting the succinate dehydrogenase genes (SDHB, SDHD and SDHC) (21.1%, 8.1%, 29.2% and 0.002%).3 The combined finding of phaeochromocytomas and pancreatic neuroendocrine tumours in a young healthy patient made VHL the single most likely aetiology, as these two findings have been associated with VHL syndrome. Our patient had no additional physical examination findings, which is also consistent with VHL syndrome. This contrasts with the café au lait macules found frequently in individuals with neurofibromatosis type 1, for example. VHL has an autosomal dominant inheritance, but can also arise spontaneously in younger people, such as in our case. Notably, these phaeochromocytomas are non-epinephrine secreting and have normal urinary concentrations of epinephrine and normetanephrine, a pattern that we found in our analysis of this case.4 The only other genetic syndrome with this characteristic pattern of catecholamines and metanephrines are the succinate dehydrogenase mutations (SDHB/D) that also have normal urinary concentrations of epinephrine/epinephrine and normetanephrine. Unlike VHL, however, SDHB/D syndromes present with octreotide-avid extra-adrenal paragangliomas, which we did not detect in our patient using whole-body MIBG.5While awaiting our genetic confirmation of VHL, which took several weeks to be completed, we carried out several investigations broadly related to other possible genetic syndromes associated with phaeochromocytomas. We did not find elevated urinary concentrations of epinephrine, which would be expected in both MEN2 and NF-1 syndromes. MEN2A was also felt to be less likely as these individuals classically present early with hyperparathyroidism and medullary thyroid cancer. We found no evidence of primary hyperparathyroidism or thyroid carcinoma as no thyroid nodules or biomarkers were detected (normal calcium, PTH, calcitonin and benign thyroid ultrasound). MEN2B and NF-1 are also associated with distinct physical examination findings that were not present in our patient, making these underlying genetic defects less likely. It would be expected in MEN2B that a marfanoid habitus or mucosal neuromas would be present. In contrast, in NF-1, it is common to be able to find multiple cutaneous neurofibromas, café au lait or Lisch nodules on examination, none of which were present.5Genetic sequencing reported from the Hereditary Endocrine Cancer Panel at the Children’s Hospital of Philadelphia confirmed a VHL gene mutation localised to R167W that had been previously reported in a kindred from Newfoundland (Canada); none of the other genes in the panel were found to be pathogenic variants (CDC73, CDKN1B, MAX, MEN1, PRKAR1A, PTEN, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127 and TP53). Interestingly, she has no known family history of ancestors living in that region of Canada.VHL is a syndrome associated with multiple comorbidities, but the most common are bilateral phaeochromocytomas, hemangioblastomas of the brain, cord and eyes, and pancreatic neuroendocrine tumours/cysts.5 Many of these tumours are occult in younger patients and are only found on dedicated imaging and specific biochemical testing. As we clinically suspected, VHL was genetically confirmed in our patient, and imaging dedicated to detecting these additional tumours was done, which ultimately detected multiple lumbar and thoracic hemangioblastomas.Go to:TreatmentThe patient was discharged home prior to the surgical removal of the phaeochromocytomas and prior to genetic confirmation of the diagnosis by genetics, as she was clinically stable with medically normalised blood pressure and without end-organ damage. Pending her adrenalectomy, her blood pressure was controlled as an outpatient by ramipril, amlodipine and prazosin. She was referred out-of-province to a surgical team with national expertise in neuroendocrine tumours. The patient was sent to the Neuroendocrine Surgery Centre in Calgary, Alberta. There, a discussion of surgical options was discussed by the surgical team and ultimately decided on a laparoscopic bilateral total adrenalectomy, the usual surgical practice for bilateral phaeochromocytomas at that centre. This was followed by her return to Calgary several weeks later for a modified Whipple procedure, which included a partial pancreatectomy to remove the octreotide-positive uncinate pancreatic lesion plus enucleation of the two additional solid pancreatic masses. On receiving the confirmation of the VHL gene mutations, she was counselled and supported regarding her VHL diagnosis from our local medical genetics team.Go to:Outcome and follow-upThe surgery normalised the biochemical excess of catecholamines and metanephrines from the phaeochromocytomas and all associated symptoms improved, along with normalisation of her blood pressure off all antihypertensive medications. As anticipated, the bilateral adrenalectomy resulted in adrenal insufficiency. Thus, she was immediately initiated on both glucocorticoid and mineralocorticoid replacement therapy and counselled regarding sick days and stress management to avoid adrenal crises. In addition, she also started dehydroepiandrosterone (DHEA) supplementation for the loss of adrenal androgens. The modified Whipple was successful and resulted in no loss of pancreatic exocrine or endocrine function. Her endogenous insulin production was maintained, with preserved postprandial C-peptide and normal blood glucose levels, without the need for medical therapy or pancreatic support.In the month after the modified-Whipple procedure, the patient had vomiting due to mucosal thickening at the anastomosis site between the stomach and the small bowel that resolved with conservative treatment. A repeat MRI 3 months after the modified-Whipple procedure found postsurgical changes with no concerning findings, acknowledging that normal postoperative findings may resemble pathological changes, such as fluid collection or ischaemia.6 Clinical follow-up confirmed there was no need for insulin or pancreatic enzymes and that she had recovered well physically with a return to normal activities. To continue monitoring for pNET, a postoperative baseline linear endoscopic oesophagogastroduodenal ultrasound was performed that visualised the three small cysts remaining within the pancreas, all without malignant features. These will also be subject to ongoing surveillance.The R167W variant of the VHL gene, as was found in our case, results in the amino acid substitution of arginine (R) for tryptophan (W) at position 167. This VHL mutation is associated with phaeochromocytomas and pancreatic cysts and tumours, but also haemangiomas, endolymphatic sac tumours, renal clear cell cysts and renal carcinomas, which may be clinically silent. This led us to initiate a multimodal surveillance plan and we detected small hemangioblastomas along the cervical and thoracic spine using dedicated spinal MRI imaging. Fortunately, auditory testing looking for early signs of endolymphatic sac tumours, ophthalmic evaluation for retinal angiomas and renal CT screening for renal cell carcinoma were all negative.She will be followed long term by a variety of specialists to perform ongoing dilated ophthalmologic assessment, neurological examinations and formal audiological evaluations. In addition to these clinical assessments, the patient will also be annually assessed by MRI of the brain and spinal cord and abdominal imaging. Annual laboratory testing of the patient’s urine for metanephrine, normetanephrine and chromogranin A were also scheduled. This schedule of surveillance is per the methodology put forward by the Danish national guidelines for the diagnosis and surveillance of VHL syndrome.7
PatientID: None
KindredID: 1
Case: F, 25Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: No family history of endocrinopathies. There was no family history of phaeochromocytomas or familial syndromes. R167W (missense) VHL variant was previously reported in a kindred from Newfoundland
CasePresentingHPOs: HP:0002315; HP:0031217; HP:0000975; HP:0000822; HP:0006748; HP:0001737; HP:0030405; HP:0009713 (Headache, Hot flashes, Hyperhidrosis, Hypertension, Adrenal pheochromocytoma, Pancreatic cysts, Pancreatic endocrine tumor, Spinal hemangioblastoma)
CaseHPOFreeText: 2-year history of progressive intermittent headaches, hot flushes, diaphoresis and hypertension. She presented to the emergency department at the 2-month mark with a severe headache and a confirmed increase in blood pressure. Her only other medication was an oral contraceptive, which had been taken long term. She is a non-smoker and non-drinker with no comorbidities, no recreational drug use. Renal Doppler ultrasound found a unilateral left adrenal mass. Given the biochemical evidence for a (bilateral) phaeochromocytoma, an abdominal MRI with gadolinium contrast was performed. This study confirmed the presence of the left adrenal mass and a smaller adrenal mass on the right. The same MRI incidentally found multiple lesions in the pancreas that were later confirmed to be neuroendocrine tumours and pancreatic cysts. Later imaging dedicated to detecting these tumours was done, which ultimately detected multiple lumbar and thoracic hemangioblastomas.
CaseNotHPOs: HP:0001649; HP:0001962; HP:0002094; HP:0002027; HP:0012378; HP:0001824; HP:0001920; HP:0002668; HP:0005584; HP:0009711; HP:0030393 (Tachycardia, Palpitations, Dyspnea, Abdominal pain, Fatigue, Weight loss, Renal artery stenosis, Paraganglioma, Renal cell carcinoma, Retinal capillary hemangioma, Endolymphatic sac tumor)
CaseNotHPOFreeText: She denied current or past symptoms of episodic or sustained tachycardia, palpations, dyspnoea, abdominal pain, fatigue or weight loss. Renal Doppler ultrasound ruled out renal artery stenosis. The activity was limited to the adrenal glands with no other body sites of increased uptake reported, making paragangliomas or distant metastasis unlikely. Fortunately, auditory testing looking for early signs of endolymphatic sac tumours, ophthalmic evaluation for retinal angiomas and renal CT screening for renal cell carcinoma were all negative.
CasePreviousTesting: MAX/TMEM127SDHA/SDHB/SDHC/SDHD/SDHAF2
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R167W (c.499C>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 2218, https://www.ncbi.nlm.nih.gov/clinvar/variation/2218/
CAID: N/A
gnomAD: 0.000007954, https://gnomad.broadinstitute.org/variant/3-10191506-C-T
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: R167W (c.499C>T)
MultipleGeneVariants: N/A